The NANOS Annual Meeting Neuro-Ophthalmology Collection: Presentations from the annual meeting of the North American Neuro-Ophthalmology Society (NANOS), a professional organization of more than 600 members who are fully trained ophthalmologists or neurologists. Contains records from the first meeting in 1975 to the present.
NOVEL: https://novel.utah.edu/
TO
Filters: Collection: ehsl_novel_nam
1 - 25 of 3
| Title | Creator | Description | Identifier | ||
|---|---|---|---|---|---|
| 1 |
 |
Expanded Access Program (EAP) in Leber's Hereditary Optic Neuropathy (LHON) Patients Treated for 24 Months (Slides) | Thomas Klopstock, Xavier Llòria, Magda Silva, Rudolph Guenther, Felice Lob, Bettina Von Livonius, Claudia Catarino | LHON is a mitochondrial genetic disorder resulting in severe bilateral central VA loss. Three primary mitochondrial DNA mutations cause over 90% of cases. Data from idebenone EAP for patients with LHON receiving treatment for at least 24 months were analyzed to assess rate of clinically-relevant rec... | 20200310_nanos_sciplatform3_06-slides |
| 2 |
 |
Expanded Access Program (EAP) in Leber's Hereditary Optic Neuropathy (LHON) Patients Treated for 24 Months (PDF) | Thomas Klopstock, Xavier Llòria, Magda Silva, Rudolph Guenther, Felice Lob, Bettina Von Livonius, Claudia Catarino | LHON is a mitochondrial genetic disorder resulting in severe bilateral central VA loss. Three primary mitochondrial DNA mutations cause over 90% of cases. Data from idebenone EAP for patients with LHON receiving treatment for at least 24 months were analyzed to assess rate of clinically-relevant rec... | 20200310_nanos_sciplatform3_06-pdf |
| 3 |
 |
Expanded Access Program (EAP) in Leber's Hereditary Optic Neuropathy (LHON) Patients Treated for 24 Months (Video) | Thomas Klopstock, Xavier Llòria, Magda Silva, Rudolph Guenther, Felice Lob, Bettina Von Livonius, Claudia Catarino | LHON is a mitochondrial genetic disorder resulting in severe bilateral central VA loss. Three primary mitochondrial DNA mutations cause over 90% of cases. Data from idebenone EAP for patients with LHON receiving treatment for at least 24 months were analyzed to assess rate of clinically-relevant rec... | 20200310_nanos_sciplatform3_06 |
1 - 25 of 3